Collateral Circulation, Any SiteNCT03311386
Intracranial Collaterals in Acute Stroke and Clinical Outcome
An observational study of Collateral Circulation, Any Site, run by Assiut University at 1 site in Egypt.
Trial summary
Assessment of the evolution of intracranial collaterals and its relationship with functional outcomes in acute ischemic stroke (AIS) patients treated with IV tissue plasminogen activator (tPA). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Collateral Circulation, Any Site
- What is being tested?
- Actilyse
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 23 Nov 2017to 1 Aug 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients with acute ischemic stroke within 4.5 hours - legible for receiving IV r TPA- admitted to Neurology department of Asyut University within 1 year (2017-2018)
Who may be able to join
None listed.
Who cannot join
- Intracranial hemorrhage (ICH) identified on baseline CT.
- Previous moderate to large stroke in the ipsilesional hemisphere.
- Modified Rankin Scale > 2 at baseline.
- Unable to have CT-angio performed due to recent estimated creatinine clearance eCCr<60 ml/min, contrast allergy or other reasons.
- Any terminal illness (patient not expected to survive > 1 year).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Collateral Vessels in Patients With Acute Ischemic Stroke Receiving Thrombolytic Therapy (Clinical and Radiological Study)
Assessment of the evolution of intracranial collaterals and its relationship with functional outcomes in acute ischemic stroke (AIS) patients treated with IV tissue plasminogen activator (tPA).
Read the detailed description
Intracranial collaterals Assessment in acute ischemic stroke In clinical practice, infarct growth does not always progress to involve the full extent of the vascular territory, even if the affected intracranial artery fails to recanalize. The presence and recruitment of various collateral channels are believed to be responsible for this phenomenon in acute ischemic stroke (AIS). These collaterals may also play an important role in influencing the safety and efficacy of acute revascularization approaches. Although blood supply from the leptomeningeal collaterals may temporarily maintain the ischemic penumbra, the persistence and effectiveness of this alternative circulatory supply is erratic and unpredictable. Some collaterals may disappear over time (collateral failure); this is one of the mechanisms responsible for clinical deterioration following initial improvement.
Conversely, dramatic resolution of initial neurologic deficits may be seen though the occluded intracranial artery did not recanalize, often attributable to the rapid improvement of cerebral perfusion via effective collateral pathways (collateral recruitment). Therefore, the temporal behavior of intracranial collaterals may play an important role in determining the functional outcome in AIS patients.
CT angiography (CTA) of the brain is acutely performed in AIS patients before or immediately after administering IV tissue plasminogen activator (tPA) The Alberta Stroke Program Early CT (ASPECTS) leptomeningeal collaterals score on CT-angiography helps in prognosticating functional outcome in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis. Leptomeningeal collaterals in AIS are dynamic, especially during the first few hours or days of AIS.
In animals, 3 different types of collaterals have been identified: transient collaterals that could be seen immediately after the stroke and last less than 90 minutes; impermanent collaterals that disappear after 90-150 minutes; and persistent collaterals, which can be seen for longer periods.
Patients with good collateral flow demonstrated less hypo perfused tissue and less infarct growth within the penumbra zone than those with poor collateral . A relationship is found between good early collaterals on pretreatment imaging and smaller infarct volume with better outcomes.
The initial state of the collateral circulation on the pretreatment CTA also has bearing on the clinical effect of the collateral recruitment on the day 2 CTA.
However, collateral recruitment with poor pretreatment collaterals was associated with poor functional outcome at 3 months and a higher risk of intracranial hemorrhage.
One plausible mechanism that delayed collateral recruitment lead to worse outcomes could be related to the maximal vasodilation in the ischemic area and how collateral recruitment in the adjacent regions may trigger a steal-like phenomenon with resultant expansion of the ischemic core. Another possible mechanism could be related to failed autoregulation in the affected vascular territory, leading to increased hyper perfusion damage with a higher chance of bleeding.
- Conditions
- Collateral Circulation, Any Site
- Being tested
- Actilyse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ActilyseDrug
Also called Alteplase
thrombolytic therapy
| Study group | Role | What they receive |
|---|---|---|
| Patients in AIS receiving actilyse | the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once Receives: Drug: Actilyse |
What is being measured
The primary outcome is the main question the study is designed to answer.
90-days functional outcome
90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke modified Rankin scale he Modified Rankin Scale (mRS) The scale runs from 0-6 0 - No symptoms.
- - No significant disability. Able to carry out all usual activities, despite some symptoms.
- - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- - Moderate disability. Requires some help, but able to walk unassisted.
- - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- - Dead.
Measured: 90 days
Secondary outcomes (1)
Early neurologic improvement
Defined as The National Institutes of Health Stroke Scale score "NIHSS" of 0 to 2 at 24 hours or an 8-point drop in NIHSS score from baseline to 24 hours.
The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Oct 2017
- Study start23 Nov 2017
- Primary completion1 Jan 2021
- Study completion1 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Collateral Circulation, Any SiteStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Mamdouh Mohammed Tawfeeq, Assiut University
- Investigators
- Essam Darwish, Professor, Principal investigator, Assiut UniversityAhmed Hamdy, Ass.Prof, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03311386
- Sponsor's protocol ID
- Collaterals and acute stroke
- Status last verified
- Sep 2021
- First submitted
- 2 Oct 2017
- Last updated
- 16 Sep 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Bang OY, Goyal M, Liebeskind DS. Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies. Stroke. 2015 Nov;46(11):3302-9. doi: 10.1161/STROKEAHA.115.010508. Epub 2015 Oct 8. No abstract available.
PubMed 26451027
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Collateral Vessels in Patients With Acute Ischemic Stroke Receiving Thrombolytic Therapy (Clinical and Radiological Study)
- ClinicalTrials.gov ID
- NCT03311386
- Acronym / sponsor ID
- Collaterals and acute stroke
- Conditions
- Collateral Circulation, Any Site
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 23 Nov 2017 (actual)
- Primary completion
- 1 Jan 2021 (actual)
- Study completion
- 1 Aug 2021 (actual)
- First posted
- 17 Oct 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessment of the evolution of intracranial collaterals and its relationship with functional outcomes in acute ischemic stroke (AIS) patients treated with IV tissue plasminogen activator (tPA).
Detailed description
Intracranial collaterals Assessment in acute ischemic stroke In clinical practice, infarct growth does not always progress to involve the full extent of the vascular territory, even if the affected intracranial artery fails to recanalize. The presence and recruitment of various collateral channels are believed to be responsible for this phenomenon in acute ischemic stroke (AIS). These collaterals may also play an important role in influencing the safety and efficacy of acute revascularization approaches. Although blood supply from the leptomeningeal collaterals may temporarily maintain the ischemic penumbra, the persistence and effectiveness of this alternative circulatory supply is erratic and unpredictable. Some collaterals may disappear over time (collateral failure); this is one of the mechanisms responsible for clinical deterioration following initial improvement.
Conversely, dramatic resolution of initial neurologic deficits may be seen though the occluded intracranial artery did not recanalize, often attributable to the rapid improvement of cerebral perfusion via effective collateral pathways (collateral recruitment). Therefore, the temporal behavior of intracranial collaterals may play an important role in determining the functional outcome in AIS patients.
CT angiography (CTA) of the brain is acutely performed in AIS patients before or immediately after administering IV tissue plasminogen activator (tPA) The Alberta Stroke Program Early CT (ASPECTS) leptomeningeal collaterals score on CT-angiography helps in prognosticating functional outcome in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis. Leptomeningeal collaterals in AIS are dynamic, especially during the first few hours or days of AIS.
In animals, 3 different types of collaterals have been identified: transient collaterals that could be seen immediately after the stroke and last less than 90 minutes; impermanent collaterals that disappear after 90-150 minutes; and persistent collaterals, which can be seen for longer periods.
Patients with good collateral flow demonstrated less hypo perfused tissue and less infarct growth within the penumbra zone than those with poor collateral . A relationship is found between good early collaterals on pretreatment imaging and smaller infarct volume with better outcomes.
The initial state of the collateral circulation on the pretreatment CTA also has bearing on the clinical effect of the collateral recruitment on the day 2 CTA.
However, collateral recruitment with poor pretreatment collaterals was associated with poor functional outcome at 3 months and a higher risk of intracranial hemorrhage.
One plausible mechanism that delayed collateral recruitment lead to worse outcomes could be related to the maximal vasodilation in the ischemic area and how collateral recruitment in the adjacent regions may trigger a steal-like phenomenon with resultant expansion of the ischemic core. Another possible mechanism could be related to failed autoregulation in the affected vascular territory, leading to increased hyper perfusion damage with a higher chance of bleeding.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients in AIS receiving actilyse | – | Drug: Actilysethe patients will receive actilyse intaravenously in a dose of 0.9mg/kg once |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients with acute ischemic stroke within 4.5 hours - legible for receiving IV r TPA- admitted to Neurology department of Asyut University within 1 year (2017-2018)
Key inclusion criteria (0 listed)
Key exclusion criteria (5 listed)
- Intracranial hemorrhage (ICH) identified on baseline CT.
- Previous moderate to large stroke in the ipsilesional hemisphere.
- Modified Rankin Scale > 2 at baseline.
- Unable to have CT-angio performed due to recent estimated creatinine clearance eCCr<60 ml/min, contrast allergy or other reasons.
- Any terminal illness (patient not expected to survive > 1 year).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ActilyseAlso: Alteplasethrombolytic therapy | Drug | Patients in AIS receiving actilyse |
Primary outcome
90-days functional outcome
Time frame: 90 days
90-day modified Rankin Score (mRS) 0-2 or equal to the pre-stroke modified Rankin scale he Modified Rankin Scale (mRS) The scale runs from 0-6 0 - No symptoms. 1. - No significant disability. Able to carry out all usual activities, despite some symptoms. 2. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. - Moderate disability. Requires some help, but able to walk unassisted. 4. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. - Dead.
1 secondary outcome
Early neurologic improvement
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2021.
- Background: PubMed 26451027Bang OY, Goyal M, Liebeskind DS. Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies. Stroke. 2015 Nov;46(11):3302-9. doi: 10.1161/STROKEAHA.115.010508. Epub 2015 Oct 8. No abstract available.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Essam Darwish, Professor principal investigator
Assiut University
Ahmed Hamdy, Ass.Prof study director
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Collateral Circulation, Any Site, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
90-days functional outcome (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03311386, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2021; AzTrials last refreshed its copy on 8 Nov 2026.